Now showing items 1-2 of 2

  • Höglander, Elen K; Nord, Silje; Wedge, David C; Lingjærde, Ole C; Silwal-Pandit, Laxmi; Gythfeldt, Hedda v; Vollan, Hans K M; Fleischer, Thomas; Krohn, Marit; Schlitchting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit M; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebraaten, Olav; Kristensen, Vessela (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) ...
  • Høglander, Elen; Nord, Silje; Wedge, David C; Lingjærde, Ole Christian; Silwal-Pandit, Laxmi; Gythfeldt, Hedda; Vollan, Hans Kristian Moen; Fleischer, Thomas; Krohn, Marit; Schlichting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit Muri; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebråten, Olav; Kristensen, Vessela N. (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    Background: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...